Why the study?
Do serum levels of IGFBP-2 and IGFBP-3 correlate with tumor markers in patients with epithelial ovarian cancer?
Do serum levels of IGFBP-2 and IGFBP-3 correlate with tumor markers in patients with epithelial ovarian cancer?
Serum IGFBP-2 levels are elevated in epithelial ovarian cancer and correlate with CA 125, suggesting potential utility as an additional tumor marker.
This is the authors' abstract. We don't add key points for this paper.
Insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) recently have been shown to play a physiological role in the female genital system, including the ovarian follicular system. However, little is known about the role of the IGF system in malignant ovarian disease. To assess possible mutual correlations between alterations in circulating IGFBP profiles and tumuor markers in patients with epithelial ovarian cancer, we performed an RIA for IGFBP-2 and IGFBP-3 and a Western ligand blotting (WLB) in serum samples from 20 patients with epithelial ovarian cancer, 10 patients with benign ovarian tumors, and 8 healthy age-matched controls. The epithelial ovarian cancer group had a mean IGFBP-2 level that was 253% (RIA) and 105% (WLB) above that of controls. IGFBP-2 even correlated positively with the highly sensitive serum tumor marker, cancer antigen 125 (CA 125) (r = 0.71, P <0.001) but not with the less sensitive tumor-associated trypsin inhibitor. In contrast, serum IGFBP-3 (by RIA and WLB) was decreased in patients with ovarian cancer, and IGFBP-3 proteolytic activity was detectable in some of the patients. Neither IGFBP-3 nor IGFBP-3 proteolytic activity correlated with CA 125; but the former correlated inversely, and the latter positively, with tumor-associated trypsin inhibitor. In conclusion, IGFBP-2 levels are high in serum of epithelial ovarian cancer patients, and the increment in serum IGFBP-2 correlates positively with CA 125. Alterations in serum IGFBP-2 levels may therefore, serve as a potential additional marker for ovarian cancer.
Answers are grounded in this paper and cite their sources.
May support IGFBP-2 as adjunct marker in ovarian cancer; leaves open prospective validation before any clinical use.
No takes yet. Share an insight, caveat, or question.
Allan Flyvbjerg (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: